Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Evelien Bergrath"'
Autor:
Kyle Fahrbach, Jialu Tarpey, Evelien Bergrath Washington, Rachel Hughes, Howard Thom, Maureen P. Neary, Amy Cha, Robert Gerber, Joseph C. Cappelleri
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 6, Pp 1441-1444 (2020)
The authors would like to replace 2 small sections of the published manuscript that refer to a qualitative review of safety data for included studies (together with an associated safety table), to provide some further clarifications on these safety d
Externí odkaz:
https://doaj.org/article/bca3862da68f4ffd9fd2703922160fb0
Autor:
Marissa Blieden Betts, Pratik Rane, Evelien Bergrath, Madhura Chitnis, Mohit Kumar Bhutani, Claudia Gulea, Yi Qian, Guillermo Villa
Publikováno v:
Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-12 (2020)
Abstract Objective Identify the most recent utility value estimates for cardiovascular disease (CVD) via systematic literature review (SLR) and explore trends in utility elicitation methods in the last 6 years. Methods This SLR was updated on January
Externí odkaz:
https://doaj.org/article/b86f87eed9d74558a9638bbf138ee193
Autor:
Kyle Fahrbach, Jialu Tarpey, Evelien Bergrath Washington, Rachel Hughes, Howard Thom, Maureen P. Neary, Amy Cha, Robert Gerber, Joseph C. Cappelleri
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 4, Pp 681-694 (2020)
Abstract Introduction There is a need to compare efficacy and safety profiles of crisaborole ointment, 2%, versus other topical treatments across randomized clinical trials (RCTs). We performed this review/network meta-analysis to evaluate the compar
Externí odkaz:
https://doaj.org/article/eaf84075afdd4249822d8605c1516207
Autor:
Nathan R. Hill D.Phil, Belinda Sandler MBBS, BSc, MRCP, Evelien Bergrath MSc, Dušan Milenković MSc, Ajibade O. Ashaye MD, MBA, MPH, MSc, Usman Farooqui MFPM, MSc, Alexander T. Cohen MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
There is no direct evidence comparing the 2 most commonly prescribed direct oral anticoagulants, apixaban and rivaroxaban, used for stroke prevention in nonvalvular atrial fibrillation (NVAF). A number of network meta-analyses (NMAs) of randomized co
Externí odkaz:
https://doaj.org/article/b2d4ab2d652647c2838ca0703c1c6230
Autor:
Evelien Bergrath, Robert A. Gerber, David Gruben, Tatjana Lukic, Charles Makin, Gene Wallenstein
Publikováno v:
International Journal of Rheumatology, Vol 2017 (2017)
Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-modifying antirheumatic drugs (DMARDs) versus biological DMARD
Externí odkaz:
https://doaj.org/article/21c782550cd24a0c8dea63f818a34c3b
Publikováno v:
Risks, Vol 2, Iss 2, Pp 146-170 (2014)
In 2006, the Netherlands commenced market based reforms in its health care system. The reforms included selective contracting of health care providers by health insurers. This paper focuses on how health insurers may increase their market share on th
Externí odkaz:
https://doaj.org/article/0dc25449d82c428f8bb39df3d52a0b2d
Autor:
Steven Deitelzweig, Evelien Bergrath, Manuela di Fusco, Amiee Kang, Mirko Savone, Joseph C Cappelleri, Cristina Russ, Marissa Betts, Allie Cichewicz, Kassandra Schaible, Jialu Tarpey, Kyle Fahrbach
Publikováno v:
Future Cardiology. 18:393-405
Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation. Materials & methods: A systematic review of electronic databases yielded 7
Autor:
Amy Cha, Maureen P Neary, Jialu Tarpey, Rachel Hughes, Kyle Fahrbach, Evelien Bergrath Washington, Howard Thom, Joseph C. Cappelleri, Robert A. Gerber
Publikováno v:
Dermatology and Therapy
Autor:
Odette S. Reifsnider, Pratik Pimple, Sarah Brand, Evelien Bergrath Washington, Sharash Shetty, Nihar R. Desai
Publikováno v:
Diabetes, obesitymetabolism. 24(4)
To estimate the cost-effectiveness of sequential use of the sodium-glucose co-transporter-2 inhibitor empagliflozin and glucagon-like peptide-1 receptor agonist liraglutide after metformin in patients with type 2 diabetes (T2D) from the US payer pers
Autor:
null Odette S. Reifsnider, null Pratik Pimple, null Sarah Brand, null Evelien Bergrath Washington, null Sharash Shetty, null Nihar R. Desai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8a2c5948c975b30090d8c366a397c5d
https://doi.org/10.1111/dom.14625/v2/response1
https://doi.org/10.1111/dom.14625/v2/response1